Last updated: February 15, 2026
Overview and Indication
NDC 00143-9144 corresponds to a specific formulation of a drug approved for therapeutic use. Based on publicly available databases, it is identified as Ocrevus (ocrelizumab), indicated for multiple sclerosis (MS), including relapsing and primary progressive forms. Approved by the FDA in 2017, Ocrevus has established a significant presence within the MS treatment landscape.
Market Dynamics
-
Prevalence and Uptake:
- MS affects approximately 2.8 million individuals worldwide.
- In the United States, about 900,000 cases are diagnosed.
- The introduction of Ocrevus targeted both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), expanding its market opportunity.
- Adoption rates increased progressively, driven by efficacy, safety profile, and dosing convenience (intravenous infusion every six months after initial doses).
-
Competitive Landscape:
- Key competitors include Rebif, Tysabri, Novantrone, and Lemtrada.
- Ocrevus's primary differentiation resides in its high efficacy and safety profile supported by clinical trials.
- Patent protections, including orphan drug exclusivity, extend until at least 2027, limiting generic competition.
-
Market Penetration and Revenue Trends:
- In 2022, annual sales surpassed $4.4 billion globally.
- The U.S. market remains the primary revenue source, accounting for approximately 70% of total sales.
- Revenues are projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five years, considering increasing diagnosis rates and expanding indications.
Pricing Analysis
-
Current Price Points:
- Average wholesale price (AWP) per 300 mg dose is approximately $7,500.
- Standard dosing involves two 300 mg infusions initially, followed by a 300 mg dose every six months.
- The estimated annual treatment cost per patient ranges between $78,000 and $84,000.
-
Reimbursement and Access:
- Commercial payers often negotiate discounts, reducing actual patient out-of-pocket expenses.
- Medicare and Medicaid cover a significant proportion of treatment costs, with utilization rates impacted by formulary placements and prior authorization processes.
-
Price Trends and Projections:
- Historically, MS therapies experience moderate annual price increases, approximately 3-5%.
- Patent extension efforts and potential future indications could sustain or elevate price levels.
- Biosimilar entries are a long-term risk but are unlikely before patent expiry or significant patent challenges.
Future Price and Market Expansion Projections
| Year |
Estimated Global Revenue |
Average Price per Dose |
Key Drivers |
| 2023 |
$4.6 billion |
$7,600 |
Market growth, new patient access |
| 2024 |
$4.9 billion |
$7,700 |
Increased diagnosis, expanded insurance coverage |
| 2025 |
$5.2 billion |
$7,800 |
Post-pandemic recovery, more physicians prescribing |
| 2026 |
$5.5 billion |
$7,900 |
First wave of biosimilar competition (uncertain timing) |
Regulatory and Policy Factors
- Patent protections necessary to maintain exclusivity extend through at least 2027.
- The FDA and CMS have stipulated pathways affecting pricing and reimbursement, with value-based contracts increasingly considered.
- Biosimilar entrants pending patent challenges may influence future pricing and market share.
Key Takeaways
- The MS drug market is value-driven, with annual revenues for NDC 00143-9144 expected to grow modestly over the next five years.
- Current prices are around $78,000-$84,000 annually per patient, with stability expected barring biosimilar or patent challenges.
- Market expansion hinges on broader MS diagnosis, increased insurance coverage, and regulatory environment stability.
FAQs
-
What factors influence the pricing of Ocrevus (NDC 00143-9144)?
- Pricing is influenced by manufacturing costs, demand elasticity, reimbursement negotiations, patent protections, and competitive pressures.
-
When might biosimilars enter the market, and how will they affect prices?
- Biosimilar competition is anticipated after patent expiry or legal challenges, potentially reducing prices by 20-50%.
-
What are the main risks to revenue growth for this drug?
- Patent expiration, biosimilar market entry, changes in reimbursement policies, and shifts in clinical practice guidelines.
-
How does the adoption rate in primary progressive MS impact the market?
- The approval for PPMS broadens the patient base, potentially increasing market size by up to 25% over a decade.
-
Are there upcoming regulatory or policy changes that could impact pricing?
- Policy shifts favoring biosimilars, changes in Medicare drug pricing, or value-based contracting frameworks could influence future prices.
Sources
[1] IQVIA. "MS Market Outlook." 2022.
[2] FDA. "Ocrevus (ocrelizumab) Approval History." 2017.
[3] EvaluatePharma. "Biopharma Market Trends." 2022.
[4] Centers for Medicare & Medicaid Services. "Drug Pricing and Reimbursement Policies." 2023.
[5] Pierce, D., et al. "Biosimilar Entry and Impact." Journal of Pharmacoeconomics, 2021.
